Evoke pharma inc (EVOK)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Sep'12
Operating expenses:
Research and development

3,133

3,416

3,470

3,273

3,456

4,095

5,031

7,123

7,752

7,137

7,007

5,629

5,707

6,951

7,157

7,656

7,749

8,154

8,622

9,872

10,559

9,991

0

0

0

-

-

-

-

-

Research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

657

0

0

0

General and administrative

3,844

3,737

4,028

4,111

4,110

3,919

3,874

3,961

3,915

4,093

3,887

3,733

3,664

3,592

3,613

3,602

3,776

3,664

3,559

3,472

3,112

3,158

3,364

3,038

2,494

1,644

841

0

0

0

Total operating expenses

6,978

7,154

7,498

7,384

7,566

8,014

8,905

11,084

11,668

11,230

10,895

9,363

9,371

10,544

10,771

11,259

11,525

11,818

12,181

13,345

13,672

13,150

11,816

8,480

5,192

2,601

1,498

0

0

0

Loss from operations

-6,978

-7,154

-7,498

-7,384

-7,566

-8,014

-8,905

-11,084

-11,668

-11,230

-10,895

-9,363

-9,371

-10,544

-10,771

-11,259

-11,525

-11,818

-12,181

-13,345

-13,672

-13,150

-11,816

-8,480

-5,192

-2,601

-1,498

0

0

0

Other income:
Interest income

27

28

30

25

18

15

8

8

6

6

5

-120

-194

-268

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

Financing costs related to warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

0

0

0

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

130

0

0

0

Gain from change in fair value of warrant liability

-

-

-

-

-

-433

-2,783

-1,238

-2,500

1,005

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

82

80

0

0

0

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

Total other income

27

28

30

25

18

448

2,791

1,247

2,507

-998

-2,552

-1,867

-3,203

-204

-1,074

-296

-300

-303

-235

-161

-140

-97

-128

-124

-105

-234

-207

0

0

0

Net loss

-6,950

-7,125

-7,468

-7,359

-7,548

-7,566

-6,113

-9,837

-9,160

-12,229

-13,448

-11,230

-12,575

-10,748

-11,845

-11,555

-11,826

-12,121

-12,417

-13,507

-13,812

-13,247

-11,944

-8,605

-5,297

-2,836

-1,706

0

0

0

Net loss per share of common stock, basic

-

-

-

-

-

-

-

-

-

-0.02

-0.34

-0.11

-

-

-0.29

-0.41

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share of common stock, diluted

-

-

-

-

-

-

-

-

-

-0.07

-0.34

-0.13

-

-

-0.29

-0.41

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average shares used to compute basic net loss per share

-

-

-

-

-

-

-

-

-

15,368

15,351

15,343

-

-

10,614

7,217

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average shares used to compute diluted net loss per share

-

-

-

-

-

-

-

-

-

15,503

15,351

15,420

-

-

10,614

7,217

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share of common stock, basic and diluted

-0.07

-0.06

-0.07

-0.09

-0.11

-0.10

-0.09

-0.14

-0.13

-

-

-

-0.37

-

-

-

-0.45

-0.35

-0.42

-0.52

-0.58

-0.49

-0.63

-0.59

-0.49

-0.14

-0.41

-0.21

-0.44

-0.43

Weighted-average shares used to compute basic and diluted net loss per share

24,439

24,313

24,128

23,258

17,484

17,427

17,129

16,425

15,427

-

-

-

13,528

-

-

-

7,168

7,131

6,494

6,212

6,103

6,045

6,054

6,027

6,002

6,011

1,190

1,137

1,133

1,125